Prof. Steffen Rausch, University Hospital Tübingen, Germany
Prof. Rausch discusses the latest findings from the KEYNOTE-905 study, highlighting the potential benefits of perioperative immunotherapy for patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. He reviews key outcomes including pathological response and disease-free survival, while also examining the safety profile of the treatment strategy.
Watch the full interview for a comprehensive expert interpretation.